資源描述：
《拉米夫定聯(lián)合扶正解毒顆粒治療慢性乙型病毒性肝炎臨床觀察.pdf》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫。
1、湖北中醫(yī)學(xué)院學(xué)報(bào)2006年6月第8卷第2期50JournalofHubeiCollegeofTCMJune.2006Vol.8No.2拉米夫定聯(lián)合扶正解毒顆粒治療慢性乙型病毒性肝炎臨床觀察王嶺!張均倡!李春濤!李野平!申高洪廣東省中醫(yī)院珠海醫(yī)院廣東珠海519015摘要!目的探討拉米夫定聯(lián)合扶正解毒顆粒口服對(duì)抗HBV及護(hù)肝作用的影響方法根據(jù)肝功能有無異常分層并按11的比例隨機(jī)分組治療組58例口服拉米夫定和扶正解毒顆粒;對(duì)照組55例口服拉米夫定兩組連續(xù)治療1年結(jié)果1)治療12個(gè)月時(shí)治療組的HBV-DNA陰轉(zhuǎn)率較對(duì)照組高Pt0.05);治療組治療12個(gè)月的YMDD變異
2、率較對(duì)照組低但Py0.05;2)治療12個(gè)月時(shí)治療組的HBeAg陰轉(zhuǎn)率較對(duì)照組高Pt0.05);治療組的e系統(tǒng)的抗原抗體轉(zhuǎn)換率較對(duì)照組高Pt0.05);3)在肝功能異常的患者中治療組的復(fù)常率均較對(duì)照組高但無顯著差異結(jié)論拉米夫定聯(lián)合扶正解毒顆?？诜梢蕴岣逪BV-DNAHBeAg的陰轉(zhuǎn)率提高HBe系統(tǒng)的抗原抗體轉(zhuǎn)換率促進(jìn)肝功能恢復(fù)關(guān)鍵詞!慢性乙型病毒性肝炎;乙肝病毒脫氧核糖核酸;中西醫(yī)結(jié)合療法;扶正解毒顆粒;拉米夫定;臨床觀察中圖分類號(hào)!R259.12文獻(xiàn)標(biāo)識(shí)碼!B文章編號(hào)!1008-987X200602-0050-03AssessmentoftheraPeuti
3、cbenefitoflamivudinecombinedWithstren9thenin9bodyanddetoxicatin9decoctiononPatientsWithchronichePatitisBWangLingZhangJun-changLiChun-taoLiYe-pingShenGao-hongZhuhaiBranchofGuangdongProvincialHospitalofTCMZhuhai519015AbstractObjectiveTheaimofthisstudyWastoevaluatetheeffectofLamivudinec
4、ombinedWithStrengtheningBodyandDetoxicatingDecoctiononpatientsWithchronichepatitisB.Method113patientsWithchronichepatitisBWererandomizedtocombinedtherapygroupn=58usingLamivudineandStrengtheningBodyandDetoxicatingDecoctionandcontrolgroupn=55usingLamivudinealone.Bothlastedfor1year.Stat
5、isticprocessz-test.Results①ThenegativeconversionratesNCRsofHBV-DNAinthecombinedtherapygroupWerehigherthanthoseinthecontrolgroupeach3monthsPt0.05attheendof1yearThemutationrateofHBV-DNAinthecombinedtherapygroupWasloWerthanthatinthecontrolgroupattheendof1yearbutPy0.05.②TheNCRsofHBeAgint
6、hecombinedtherapygroupWerehigherthanthoseinthecontrolgroupeach3monthsPt0.05attheendof1year.TheconversionratesofHBeAgtoanti-HBeinthecombinedtherapygroupWerehigherthanthoseinthecontrolgroupeach3monthsPt0.05attheendsof912month.③InthepatientsWithabnormalALTthenormalizationratesofserumALT
7、inthecombinedtherapygroupWerehigherthanthoseinthecontrolgroupeach3monthsbutPy0.05each.ConclusionThesefactssuggestedthatusingLamivudinecombinedWithStrengtheningBodyandDetoxicatingDecoctioninthetreatmentWasbenefittothepatientsWithchronichepatitisB.KeyWordsChronicHepatitisBHepatitisBVir
8、usDNALamivud
